Is Sonidegib covered by medical insurance?

Sonidegib has potential for the treatment of locally advanced basal cell carcinoma (laBCC) and may also be used to treat other types of cancer. A large proportion of patients saw only clinical benefit with mild to moderate adverse events. Despite rare serious adverse events, the complete response rate (30%) was quite low for a tumor type driven primarily by mutations in the PTCH1 gene. The response rate for mBCC was even worse (<5%).

Solidegib may play an important role as an adjuvant therapy in the treatment of other cancers. Due to its observed potential effects in multiple cancer types, it can be expected that additional clinical applications of solidagib will be approved. However, although Solidegib is a potent HPI, it does not effectively inhibit non-familial Hh signaling because these signaling events bypass SMO-dependent signaling. Growing evidence suggests that certain cancer types, including pancreatic cancer, may exhibit aberrant activation of non-tumor pathways. Therefore, it would be beneficial to develop an antagonist of a common downstream Hh signaling molecule, such as an inhibitor of the Gli transcription factor.

Solidagen is a new type of drug for treating diseases. Although the original drug Solidagen has been launched in China, it has not yet entered the scope of medical insurance. Its price has not yet been determined, and domestic patients cannot yet purchase this drug. The price of Solidegib Original drug, European version specifications200mg*30 capsules per box listed overseas is around RMB 46,000 (the price may fluctuate due to the exchange rate), which is relatively expensive. The ingredients of the two drugs are basically the same. When purchasing this drug overseas, you need to choose through formal channels. Currently, there are no generic drugs of Solidagen produced and put on the market. For specific price and drug information, please consult Yaode Medical Consultant.